Multicenter Evaluation of Memory Remediation After TBI With Donepezil
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a four-site, randomized, parallel design, double-blind, placebo-controlled, 10-week
trial of donepezil 10 mg daily for verbal memory problems among adults with TBI in the
subacute or chronic recovery period. The study will recruit 160 persons with TBI and
functionally important memory problems during a four-year period of open recruitment.
The study aims are:
1. To evaluate the effects of treatment with donepezil on verbal memory as assessed by the
Hopkins Verbal Learning Test-Revised Total Trial 1-3;
2. To evaluate the effects of treatment with donepezil on memory-related activities as
measured by the Everyday Memory Questionnaire;
3. To evaluate the effects of donepezil on attention, processing speed, neuropsychiatric
symptoms, community participation, quality of life, and caregiver experiences.
Phase:
Phase 3
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Albert Einstein Healthcare Network Craig Hospital Indiana University Spaulding Rehabilitation Hospital TIRR Memorial Hermann